From the onset, Paragon 28 has provided innovative orthopedic solutions, procedural approaches and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, Charcot foot and orthobiologics. Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific auspicious day in may 2019 screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments.
Its products include plates and plating systems, screws, staples, and nails aimed to address all major foot and ankle procedures including ankle, charcot, fracture fixation, hallux valgus, hammertoe, and flatfoot. This milestone is an important achievement in the advancement of Paragon 28’s SMART 28℠strategy, which targets to provide meaningful options to their surgeon customers and significantly improve patient outcomes. The IDE of the SMART Total Talus adds to the company’s existing Patient Specific Total Talus offering by expanding use of the technology as an option for prospective total ankle replacement candidates.
Based in Englewood, CO., Paragon 28, is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedicated to improving patient lives. From the onset, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, charcot foot and orthobiologics. The company designs products with both the patient and surgeon in mind, with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent, and reproducible. From the onset, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, Charcot foot and orthobiologics.
Advancing the Science of Foot & Ankle Surgery
We update our data regularly, but information can change between updates. Confirm details with the provider you’re interested in before making a decision. Upgrade to MarketBeat All Access to add more stocks to your watchlist. One share of FNA stock can currently be purchased for approximately $13.76.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated. He covers everything from digital banking to car insurance and, whatever the topic, he aims to make it easy for consumers to get straight to the best deal. Felix has a postgraduate qualification in international journalism and is also a broadcast journalist.
Paragon 28 Stock Gains in Trading Debut, While MiNK Rebounds
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. FNA’s beta can be found in Trading Information at the top of this page.
The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado. Paragon 28 Inc is a medical devices company that develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace.
Paragon 28 To Report Second Quarter Financial Results on August 2, 2023
Paragon will not receive any proceeds from the sale of common stock offered by the selling securityholders. Paragon 28 acquired Additive Orthopaedics in June 2021, providing the Company with the first and only FDA approved Patient Specific Total Talus replacement for treatment of avascular necrosis (AVN). With approval of the IDE to support future regulatory applications, the company’s SMART Total Talus is on the path to become the only device on the market intended for talar replacement in the setting of adjacent joint arthritis. Paragon 28 saw a increase in short interest during the month of August. As of August 15th, there was short interest totaling 974,200 shares, an increase of 15.5% from the July 31st total of 843,300 shares. Based on an average daily trading volume, of 262,100 shares, the short-interest ratio is presently 3.7 days.
- More value-oriented stocks tend to represent financial services, utilities, and energy stocks.
- As of August 15th, there was short interest totaling 974,200 shares, an increase of 15.5% from the July 31st total of 843,300 shares.
- Paragon 28 acquired Additive Orthopaedics in June 2021, providing the Company with the first and only FDA approved Patient Specific Total Talus replacement for treatment of avascular necrosis (AVN).
- MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.
We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn’t influence our assessment of those products. Please don’t interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder.com compares a wide range of products, providers and services but we don’t provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
If you’re interested in the numbers, Paragon’s savings deposits reached £3.6 billion in 2017. Paragon is a FTSE 250 company with over £12 billion in assets.
Since gaining its banking licence in 2014, Paragon has expanded into providing a wide range of specialist financing products for landlords and businesses, as well as its consumer banking products. According to 4 analysts, the average rating for FNA stock is “Strong Buy.” The 12-month stock price forecast is $27.25, which is an increase of 98.76% from the latest price. The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. The name “Paragon 28” was chosen by design — to never lose focus on our goal to advance the science of foot and ankle surgery.
Paragon 28 s CEO, Albert DaCosta, commented, The approval of this IDE study is another great example of our commitment to improve the lives of patients suffering from foot and ankle conditions, and it is an important advancement for our SMART 28ecosystem and total ankle portfolio. We are very pleased that the FDA has recognized the potential benefits of expanding access of this technology to more ankle patients, and we are excited to get this IDE study underway. 4 Wall Street research analysts have issued 12-month target prices for Paragon 28’s stock. On average, they expect the company’s share price to reach $28.20 in the next year. This suggests a possible upside of 104.9% from the stock’s current price. View analysts price targets for FNA or view top-rated stocks among Wall Street analysts.
Price Target and Rating
While we are independent, we may receive compensation from our partners for featured placement of their products or services. Although it’s a relatively new bank, Paragon has received plaudits for its competitive savings products in recent years. If you’re happy to manage your savings accounts online and are looking for cash ISAs that offer decent returns, Paragon may be worth a look. The bank has a range of savings accounts that are only available to existing customers, so if you do decide to open an account, you may find other products that are suitable for your saving needs. Paragon intends to use the net proceeds from the offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by Paragon, for working capital, capital expenditures and other general corporate purposes. Paragon may also use a portion of the net proceeds to acquire or invest in products, technologies or businesses that are complementary to its business; however, Paragon currently does not have any agreements or commitments to complete any such transactions.
Top institutional investors include BlackRock Inc. (3.75%), Braidwell LP (2.59%), State Street Corp (1.62%), Wasatch Advisors LP (1.52%), ArrowMark Colorado Holdings LLC (1.34%) and Geode Capital Management LLC (0.82%). Insiders that own company stock include Albert Dacosta, B Ag Bird, Frank S Bono, Kristina Wright, Lee Rosenthal, Matthew Jarboe, Mvm Partners Llp and Thomas P Schnettler. Paragon 28’s stock was trading at $19.11 at the beginning of the year. Since then, FNA shares have decreased by 28.0% and is now trading at $13.76. Founded in 1985, Paragon is one of the UK’s leading specialist lenders, with over 1.5 million customers.
Analysts Offer Insights on Healthcare Companies: Clearside Biomedical (CLSD), Gamida Cell (GMDA) and Paragon 28 (FNA)
JMP Securities and Needham & Company are acting as co-managers. BofA Securities and Piper Sandler & Co. are acting as joint book-running managers for the offering. Canaccord https://1investing.in/ Genuity is acting as a lead manager for the offering. JMP Securities, a Citizens Company, and Needham & Company are acting as co-managers for the offering.
Sign-up to receive the latest news and ratings for Paragon 28 and its competitors with MarketBeat’s FREE daily newsletter. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time. This site is protected by reCAPTCHA and the Google
Terms of Service apply. We’d like to share more about how we work and what drives our day-to-day business.